Fortis Pharmaceuticalssp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-09-16
Share capital
20 000,00 PLN
Activity description

Fortis Pharmaceuticals is a dynamic Polish pharmaceutical company that develops high-quality health products. It offers a range of dietary supplements such as Tribiolac, Gardipect, and Solvit D3, as well as medications including Ibufast Forte and Diclogel. The company focuses on improving patient health and comfort through its diverse product line.

Registered address
ul. Adama Mickiewicza 29, 40-085 Katowice, Poland
Website
fortispharmaceuticals.plWebsite active
Email
Email address current
Phone
Social media
Electronic delivery address
AE:PL-81564-40779-SUFIU-24

Financials

Revenue history (in k)

Financial insight

  • Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 6.91mMedianUSD 874.80kAverageUSD 20.30m
Net profit
This companyUSD 1.16mMedianUSD 28.22kAverageUSD 816.54k
Operating costs
This companyUSD 5.60mMedianUSD 805.63kAverageUSD 19.09m
Assets
This companyUSD 3.09mMedianUSD 541.73kAverageUSD 10.95m

Industry

Bank accounts

Registered as a VAT taxpayer on 2012-07-18. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

26 public aid cases recorded, with a total value of $309,401.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$21,246
De minimis aid (in accordance with Commission Regulation 2023/2831)
$1,573
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$24,756

Tenders

No recorded participation in tenders.

Trademarks

Fortis Pharmaceuticals holds 26 active trademarks registered with the Polish Patent Office. 1 application is pending. 2 marks have expired or were not registered. The first mark was filed in 2012.

MarkProtected until
WITAMINA D3 FORTIS(word)Nov 8, 2034
tadalafil fortis(word)May 24, 2032
DEVIR(word)May 24, 2032
Gastroprazol(word)May 24, 2032
NEOCLIN(word)Dec 14, 2031

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Szymon Dawid Kamiński – President of the Management Board
Dominik Marcin Kołodziej – Vice President of the Management Board

Manner of representation

The right and obligation to represent and conduct the affairs of the transformed company shall be vested in the management board of the transformed company, acting in accordance with the rules of representation specified by the Commercial Companies Code and the articles of association of the company operating under the business name FORTIS PHARMACEUTICALS spółka z ograniczoną odpowiedzialnością with its registered office in Katowice. The management board consists of 1 to 3 members appointed by a resolution of the meeting of partners. The management board is appointed for an indefinite period; however, the partners’ resolution appointing the management board may provide otherwise. Szymon Kamiński shall be President of the Management Board of the transformed company, and Dominik Kołodziej shall be Vice-President of the Management Board.

Ownership

OwnerSharesShare valueStake
Szymon Dawid Kamiński (46)
100$2,701.2450%
Dominik Marcin Kołodziej (45)
100$2,701.2450%

Competitors

Name
Livistosp. z o.o.
Nutropharmasp. z o.o.
PolypharmS.A.
Viridissp. z o.o.
Diather Petrusewiczsp. k.
Nutratrade Polskasp. z o.o.
Provital Polskasp. z o.o.
Bestpharmasp. z o.o.
Steriwundsp. z o.o.
Farmbudsp. z o.o.

FAQ

Last updated: 2026-07-17